Download PDF
Semin Liver Dis 2002; 22(4): 365-378
DOI: 10.1055/s-2002-35706
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Treatment of Autoimmune Hepatitis

Albert J. Czaja
  • Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota
Further Information

Publication History

Publication Date:
25 November 2002 (online)

    Permissions and Reprints

ABSTRACT

Corticosteroid therapy is effective in all forms of autoimmune hepatitis, and the combination of prednisone and azathioprine is preferred. Remission can be achieved in 80% of patients within 3 years, and the 10- and 20-year survival rates exceed 80%. Histological cirrhosis does not affect response or longevity, and all patients with severe disease should be treated, including children, elderly adults, postmenopausal women, individuals with acute or fulminant presentations, and those without conventional autoantibodies. Relapse is common, and long-term low-dose prednisone or azathioprine therapy is preferred after multiple relapses. Sustained remission is achievable, even after relapse, in 47% within 10 years, and the long-term maintenance regimens need not be indefinite. Liver transplantation is effective, and its actuarial 10-year survival rate is 75%. Drugs such as cyclosporine, tacrolimus, and mycophenolate mofetil promise greater blanket immunosuppression, and site-specific interventions are feasible, including blocking peptides, soluble cytotoxic T lymphocyte antigen-4, cytokine manipulations, T cell vaccination, oral tolerance, and gene therapy.

KEYWORDS

Corticosteroids - azathioprine - autoimmunity

REFERENCES

  • 1 Czaja A J. Drug therapy in the management of type 1 autoimmune hepatitis.  Drugs . 1999;  57 49-68
    PubMedGoogle Scholar
  • 2 Cook G C, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis.  QJM . 1971;  40 159-185
    PubMedGoogle Scholar
  • 3 Soloway R D, Summerskill W HJ, Baggenstoss A H. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis.  Gastroenterology . 1972;  63 820-833
    PubMedGoogle Scholar
  • 4 Murray-Lyon I M, Stern R B, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis.  Lancet . 1973;  1 735-737
    PubMedGoogle Scholar
  • 5 Summerskill W HJ, Korman M G, Ammon H V, Baggenstoss A H. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared.  Gut . 1975;  16 876-883
    PubMedGoogle Scholar
  • 6 Roberts S K, Therneau T, Czaja A J. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis.  Gastroenterology . 1996;  110 848-857
    CrossrefPubMedGoogle Scholar
  • 7 Kanzler S, Lohr H, Gerken G, Galle P R, Lohse A W. Long-term management and prognosis of autoimmune hepatitis (AIH): a single center experience.  Z Gastroenterol . 2001;  39 339-348
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Davis G L, Czaja A J, Ludwig J. Development and prognosis of histologic cirrhosis in corticosteroid-treated HBsAg-negative chronic active hepatitis.  Gastroenterology . 1984;  87 1222-1227
    PubMedGoogle Scholar
  • 9 Czaja A J, Davis G L, Ludwig J, Taswell H F. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis.  Hepatology . 1984;  4 622-627
    PubMedGoogle Scholar
  • 10 Czaja A J, Ammon H V, Summerskill W HJ. Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission.  Gastroenterology . 1980;  78 518-523
    PubMedGoogle Scholar
  • 11 Hegarty J E, Nouri-Aria K T, Portmann B, Eddleston A W F L, Williams R. Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis.  Hepatology . 1983;  3 685-689
    PubMedGoogle Scholar
  • 12 Czaja A J, Manns M P, McFarlane I G, Hoofnagle J H. Autoimmune hepatitis: the investigational and clinical challenges.  Hepatology . 2000;  31 1194-1200
    CrossrefPubMedGoogle Scholar
  • 13 Bratts R, Linden M. Cytokine modulation by glucocorticosteroids: mechanisms and actions in cellular studies.  Aliment Pharmacol Ther . 1996;  10 81-90
    PubMedGoogle Scholar
  • 14 Reichardt H M, Schutz G. Glucocorticoid signaling-multiple variations of a common theme.  Mol Cell Endocrinol . 1998;  146 1-6
    CrossrefPubMedGoogle Scholar
  • 15 De Bosscher K, Vanden Berghe W, Haegeman G. Mechanisms of anti-inflammatory action and of immunosuppression by glucocorticoids: negative interference of activated glucocorticoid receptor with transcription factors.  J Neuroimmunol . 2000;  109 16-22
    CrossrefPubMedGoogle Scholar
  • 16 Almawi W Y. Molecular mechanisms of glucocorticoid effects.  Modern Aspects of Immunobiology . 2001;  2 78-82
    PubMedGoogle Scholar
  • 17 Uribe M, Go V LW. Corticosteroid pharmacokinetics in liver disease.  Clin Pharmacokinetics . 1979;  4 233-240
    PubMedGoogle Scholar
  • 18 Uribe M, Go V LW, Kluge D. Prednisone for chronic active hepatitis: pharmacokinetics and serum binding in patients with chronic active hepatitis and steroid major side effects.  J Clin Gastroenterol . 1984;  6 331-335
    PubMedGoogle Scholar
  • 19 Schalm S W, Summerskill W HJ, Go V LW. Prednisone for chronic active liver disease: pharmacokinetics, including conversion to prednisolone.  Gastroenterology . 1977;  72 910-913
    PubMedGoogle Scholar
  • 20 Johnson P J. Immunosuppressive drug mechanisms. In: McFarlane IG, Williams R, eds. Molecular Basis of Autoimmune Hepatitis Austin, TX: RG Landes 1996: 177-191
    Google Scholar
  • 21 Lennard L. Clinical implications of thiopurine methyltransferase-optimization of drug dosage and potential drug interactions.  Ther Drug Monit . 1998;  20 527-531
    CrossrefPubMedGoogle Scholar
  • 22 Schalm S W, Korman M G, Summerskill W HJ, Czaja A J, Baggenstoss A H. Severe chronic active liver disease. Prognostic significance of initial morphologic patterns.  Am J Dig Dis . 1977;  22 973-980
    CrossrefPubMedGoogle Scholar
  • 23 DeGroote J, Fevery J, Lepoutre L. Long-term follow-up of chronic active hepatitis of moderate severity.  Gut . 1978;  19 510-513
    PubMedGoogle Scholar
  • 24 Fevery J, Desmet V J, DeGroote J. Long-term follow-up and management of asymptomatic chronic active hepatitis. In: Cohen S, Soloway RD, eds. Chronic Active Liver Disease New York: Churchill Livingstone 1983: 51-64
    Google Scholar
  • 25 Gregorio G V, Portmann B, Karani J. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study.  Hepatology . 2001;  33 544-553
    CrossrefPubMedGoogle Scholar
  • 26 Wang K K, Czaja A J. Prognosis of corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis in postmenopausal women: a retrospective analysis.  Gastroenterology . 1989;  97 1288-1293
    PubMedGoogle Scholar
  • 27 Schramm C, Kanzler S, Meyer zum Buschenfelde K-H, Galle P R, Lohse A W. Autoimmune hepatitis in the elderly.  Am J Gastroenterol . 2001;  96 1587-1591
    CrossrefPubMedGoogle Scholar
  • 28 Steven M M, Buckley J D, Mackay I R. Pregnancy in chronic active hepatitis.  QJM . 1979;  48 519-531
    PubMedGoogle Scholar
  • 29 Heneghan M A, Norris S M, O'Grady J G, Harrison P M, McFarlane I G. Management and outcome of pregnancy in autoimmune hepatitis.  Gut . 2001;  48 97-102
    CrossrefPubMedGoogle Scholar
  • 30 Varma R R, Michelsohn N H, Borkowf H I, Lewis J D. Pregnancy in cirrhotic and noncirrhotic portal hypertension.  Obstet Gynecol . 1977;  50 217-222
    PubMedGoogle Scholar
  • 31 Czaja A J, Rakela J, Ludwig J. Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis.  Gastroenterology . 1988;  95 448-453
    PubMedGoogle Scholar
  • 32 Nikias G A, Batts K P, Czaja A J. The nature and prognostic implications of autoimmune hepatitis with an acute presentation.  J Hepatol . 1994;  21 866-871
    CrossrefPubMedGoogle Scholar
  • 33 Davis G L, Czaja A J, Baggenstoss A H, Taswell H F. Prognostic and therapeutic implications of extreme serum aminotransferase elevation in chronic active hepatitis.  Mayo Clin Proc . 1982;  57 303-309
    PubMedGoogle Scholar
  • 34 Alvarez F, Berg P A, Bianchi F B. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis.  J Hepatol . 1999;  31 929-938
    CrossrefPubMedGoogle Scholar
  • 35 Czaja A J, Carpenter H A, Santrach P J, Moore S B, Homburger H A. The nature and prognosis of severe cryptogenic chronic active hepatitis.  Gastroenterology . 1993;  104 1755-1761
    PubMedGoogle Scholar
  • 36 Ben Ari Z, Mehta A, Lennard L, Burroughs A K. Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis.  J Hepatol . 1995;  23 351-354
    CrossrefPubMedGoogle Scholar
  • 37 Heneghan M A, McFarlane I G. Current and novel immunosuppressive therapy for autoimmune hepatitis.  Hepatology . 2002;  35 7-13
    CrossrefPubMedGoogle Scholar
  • 38 Yates C R, Krynetski E Y, Loennechen T. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance.  Ann Intern Med . 1997;  126 608-614
    PubMedGoogle Scholar
  • 39 Rosenkrantz J G, Githens J H, Cox S M, Kellum D L. Azathioprine (Imuran) and pregnancy.  Am J Obstet Gynecol . 1967;  97 387-394
    PubMedGoogle Scholar
  • 40 Wang K K, Czaja A J, Beaver S J, Go V LW. Extrahepatic malignancy following long-term immunosuppressive therapy of severe hepatitis B surface antigen-negative chronic active hepatitis.  Hepatology . 1989;  10 39-43
    PubMedGoogle Scholar
  • 41 Maggiore G, Bernard O, Hadchouel M. Treatment of autoimmune chronic active hepatitis in childhood.  J Pediatr . 1984;  104 839-844
    PubMedGoogle Scholar
  • 42 Roberts E A. Autoimmune hepatitis.  Indian J Pediatr . 1995;  62 525-531
    PubMedGoogle Scholar
  • 43 Czaja A J, Wolf A M, Baggenstoss A H. Laboratory assessment of severe chronic active liver disease (CALD): correlation of serum transaminase and gamma globulin levels with histologic features.  Gastroenterology . 1981;  80 687-692
    PubMedGoogle Scholar
  • 44 Schalm S W, Ammon H V, Summerskill W HJ. Failure of customary treatment in chronic active liver disease: causes and management.  Ann Clin Res . 1976;  8 221-227
    PubMedGoogle Scholar
  • 45 Czaja A J, Beaver S J, Shiels M T. Sustained remission following corticosteroid therapy of severe HBsAg-negative chronic active hepatitis.  Gastroenterology . 1987;  92 215-219
    PubMedGoogle Scholar
  • 46 Czaja A J. Low dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis.  Hepatology . 1990;  11 1044-1049
    PubMedGoogle Scholar
  • 47 Stellon A J, Keating J J, Johnson P J, MacFarlane I G, Williams R. Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal.  Hepatology . 1988;  8 781-784
    PubMedGoogle Scholar
  • 48 Johnson P J, McFarlane I G, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis.  N Engl J Med . 1995;  333 958-963
    CrossrefPubMedGoogle Scholar
  • 49 Czaja A J, Menon K VN, Carpenter H A. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis.  Hepatology . 2002;  35 890-897
    CrossrefPubMedGoogle Scholar
  • 50 Seaberg E C, Belle S H, Beringer K C, Schivins J L, Detre K M. Liver transplantation in the United States from 1987-1998; updated results from the Pitt-UNOS liver transplant registry. In: Cecka JM, Terasaki PI, eds. Clinical Transplants 1998 Los Angeles, CA: UCLA Tissue Typing Laboratories 1999: 17-37
    Google Scholar
  • 51 Sanchez-Urdazpal L, Czaja A J, van Hoek B, Krom R AF, Wiesner R H. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis.  Hepatology . 1992;  15 215-221
    PubMedGoogle Scholar
  • 52 González-Koch A, Czaja A J, Carpenter H A. Recurrent autoimmune hepatitis after orthotopic liver transplantation.  Liver Transplantation . 2001;  4 302-310
    PubMedGoogle Scholar
  • 53 Hayashi M, Keefe E B, Krams S M. Allograft rejection after liver transplantation for autoimmune liver disease.  Liver Transpl Surg . 1998;  4 208-214
    CrossrefPubMedGoogle Scholar
  • 54 Kerkar N, Hadzic N, Davies E T. De-novo autoimmune hepatitis after liver transplantation.  Lancet . 1998;  353 409-413
    PubMedGoogle Scholar
  • 55 Heneghan M A, Portmann B C, Norris S M. Graft dysfunction mimicking autoimmune hepatitis following liver transplantation in adults.  Hepatology . 2001;  34 464-470
    CrossrefPubMedGoogle Scholar
  • 56 Salcedo M, Vaquero J, Banares R. Response to steroids in de novo autoimmune hepatitis after transplantation.  Hepatology . 2002;  35 349-356
    CrossrefPubMedGoogle Scholar
  • 57 Czaja A J. Autoimmune hepatitis after liver transplantation and other lessons of self intolerance.  Liver Transpl . 2002;  8 505-513
    CrossrefPubMedGoogle Scholar
  • 58 Dustin M L, Shaw A S. Costimulation: building an immunological synapse.  Science . 1999;  283 649-650
    CrossrefPubMedGoogle Scholar
  • 59 Calderhead D M, Kosaka Y, Manning E M, Noelle R J. CD40-CD154 interactions in B-cell signaling.  Curr Top Microbiol Immunol . 2000;  245 73-99
    PubMedGoogle Scholar
  • 60 McCoy K D, Le Gros G. The role of CTLA-4 in the regulation of T cell immune responses.  Immunol Cell Biol . 1999;  77 1-10
    CrossrefPubMedGoogle Scholar
  • 61 Alvarez F, Ciocca M, Canero-Velasco C. Short-term cyclosporine induces a remission of autoimmune hepatitis in children.  J Hepatol . 1999;  30 222-227
    CrossrefPubMedGoogle Scholar
  • 62 Malekzadeh R, Nasser-Moghaddam S, Kaviani M-J. Cyclosporin-A is a promising alternative to corticosteroids in autoimmune hepatitis.  Dig Dis Sci . 2001;  46 1321-1327
    CrossrefPubMedGoogle Scholar
  • 63 Van Thiel H D, Wright H, Carroll P. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial.  Am J Gastroenterol . 1995;  90 771-776
    PubMedGoogle Scholar
  • 64 Richardson P D, James P D, Ryder S D. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis patients resistant to or intolerant of azathioprine.  J Hepatol . 2000;  33 371-375
    CrossrefPubMedGoogle Scholar
  • 65 Czaja A J, Lindor K D. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis.  Gastroenterology . 2000;  119 1312-1316
    PubMedGoogle Scholar
  • 66 Pratt D S, Flavin D P, Kaplan M M. The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine.  Gastroenterology . 1996;  110 271-274
    PubMedGoogle Scholar
  • 67 Markham A, Bryson H M. Deflazacort. A review of its pharmacological properties and therapeutic efficacy.  Drugs . 1995;  50 317-333
    CrossrefPubMedGoogle Scholar
  • 68 Deflazacort-an alternative to prednisolone? Drug Ther Bull . 1999 37: 57-58
    Google Scholar
  • 69 Rebollo Bernardez J, Cifuentes Mimoso C, Pinar Moreno A. Deflazacort for long-term maintenance of remission in type 1 autoimmune hepatitis.  Rev Esp Enferm Dig . 1999;  91 630-638
    PubMedGoogle Scholar
  • 70 Czaja A J, Carpenter H A, Lindor K D. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial.  Hepatology . 1999;  30 1381-1386
    CrossrefPubMedGoogle Scholar
  • 71 Nakamura K, Yoneda M, Yokohama S. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis.  J Gastroenterol Hepatol . 1998;  13 490-495
    PubMedGoogle Scholar
  • 72 Fridkis-Hareli M, Rosloniec E F, Fugger L, Strominger J L. Synthetic peptides that inhibit binding of the collagen type II 261-273 epitope to rheumatoid arthritis-associated HLA-DR1 and -DR4 molecules and collagen-specific T-cell responses.  Hum Immunol . 2000;  61 640-650
    CrossrefPubMedGoogle Scholar
  • 73 Guinan E C, Boussiotis V A, Neuberg D. Transplantation of anergic histoincompatible bone marrow allografts.  N Engl J Med . 1999;  340 1704-1714
    CrossrefPubMedGoogle Scholar
  • 74 Wardrop R M, Whitacre C C. Oral tolerance in the treatment of inflammatory autoimmune diseases.  Inflamm Res . 1999;  48 106-119
    CrossrefPubMedGoogle Scholar
  • 75 Lohse A W, Dienes H P, Meyer zum Buschenfelde K-H. Suppression of murine experimental autoimmune hepatitis by T-cell vaccination or immunosuppression.  Hepatology . 1998;  27 1536-1543
    CrossrefPubMedGoogle Scholar
  • 76 Rutgeerts P, D'Haens G, Targan S. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.  Gastroenterology . 1999;  117 761-769
    CrossrefPubMedGoogle Scholar
  • 77 Nelson D R, Lauwers G Y, Lau J Y, Davis G L. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot study of interferon nonresponders.  Gastroenterology . 2000;  118 655-660
    CrossrefPubMedGoogle Scholar
  • 78 Touhy V K, Mathisen P M. Gene therapy for autoimmune diseases. In: Manns MP, Paumgartner G, Leuschner U, eds. Immunology and Liver Falk Symposium 114. Dordrecht, The Netherlands: Kluwer Academic 2000: 376-385
    Google Scholar
      >